News

  • xxbrane logo402x.png.pagespeed.ic.1L1i32ZW9 June 22, 2016

    Xbrane Biopharma initiates scale-up of production of its Ranibizumab biosimilar Xlucane at Biotechpharma ahead of plan

    Xbrane Biopharma AB has entered into an agreement with Biotechpharma UAB regarding scale-up of the production of Xlucane, Xbrane’s Ranibizumab biosimilar, in GMP approved facility, further process optimization, the required biochemical characterization and development of the CMC documentation

  • eurostars June 16, 2016

    Biotechpharma acquires another Eurostars project

     

    Biotechpharma is glad to announce that the final confirmation by EUREKA secretariat was issued for ABC2ALL project which starts in November 2016 where Biotechpharma is part of consortia comprising companies from Netherlands, France, United Kingdom and Lithuania. Consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens.
     
    Biotechpharma would like to thank everyone who has helped to get this project approved and consortia members for entrusting Biotechpharma with important role and giving an opportunity to be a part of a continuous advance in the field of biopharmaceuticals
    Biotechpharma is glad to announce that the final confirmation by EUREKA secretariat was issued for ABC2ALL project which starts in November 2016 where Biotechpharma is part of consortia comprising companies from Netherlands, France, United Kingdom and Lithuania. Consortium will develop a novel therapeutic strategy to treat b-cell chronic lymphocytic leukemia (CLL). The consortium will design, produce and validate a therapeutic bispecific monoclonal antibody (mAb) that simultaneously targets two specific receptors expressed on malignant B-cells. This will provide improved efficacy, specificity, and safety when compared to the current treatment regimens. Biotechpharma would like to thank everyone who has helped to get this project approved and consortia members for entrusting Biotechpharma with important role and giving an opportunity to be a part of a continuous advance in the field of biopharmaceuticals.

  • May 12, 2016

    "Biotechpharma" - Lietuvos metų eksportuotoja

  • April 05, 2016

    UAB "Biotechpharma" vadovo indėlio į Lietuvos mokslą įvertinimas

  • sekmingaismall rounds December 21, 2015

    UAB "Biotechpharma" - Sėkmingai dirbanti įmonė

    header-metu.JPG